Medical Science Liaison (Great Lakes)
ArcellxFull Time
Senior (5 to 8 years)
Candidates should possess strong scientific acumen with the ability to translate complex data into meaningful discussions with external experts. Excellent relationship-building skills and comfort engaging with rheumatologists, researchers, and healthcare providers are essential. A demonstrated understanding of clinical trial operations and site engagement, along with familiarity with the U.S. healthcare environment spanning academic and community rheumatology practices, is required. The ability to collaborate effectively across diverse internal functions is also necessary.
The Medical Science Liaison (MSL) will serve as a scientific expert, fostering partnerships with healthcare professionals, clinical researchers, and advocacy groups in neurological disorders. Responsibilities include delivering high-quality scientific exchange, providing education on emerging data, supporting clinical trial execution, and capturing insights to inform medical strategy, with a primary focus on advancing telitacicept for Sjogren’s Disease. Key duties involve building and maintaining expertise in the company’s rheumatology pipeline, serving as a trusted scientific resource, partnering across Medical Affairs, Clinical Development, and Commercial, identifying opportunities for scientific communication and evidence generation, and participating in rheumatology-focused scientific meetings. The role also entails establishing and nurturing relationships with key opinion leaders, facilitating scientific exchange, engaging investigators and clinical trial sites, contributing to evidence generation, and adapting communication styles for different practice settings. Furthermore, the MSL will collaborate closely with internal teams to ensure scientific alignment and launch readiness, provide compliant responses to medical inquiries, and support advisory boards and educational initiatives.
Develops targeted therapies for blood cancers
Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from competitors is their strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform and pipeline of therapies. They generate revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. The company's mission is to transform the treatment landscape for blood cancers by providing innovative therapies that prioritize patient safety and efficacy.